Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV001903664 | SCV002170836 | uncertain significance | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with aspartic acid, which is acidic and polar, at codon 1631 of the ARFGEF2 protein (p.Asn1631Asp). This variant is present in population databases (rs370851843, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with ARFGEF2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1405254). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002555395 | SCV003696398 | uncertain significance | Inborn genetic diseases | 2022-03-31 | criteria provided, single submitter | clinical testing | The c.4891A>G (p.N1631D) alteration is located in exon 36 (coding exon 36) of the ARFGEF2 gene. This alteration results from a A to G substitution at nucleotide position 4891, causing the asparagine (N) at amino acid position 1631 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |